摘要
目的对比不同Child分级的高HBVDNA滴度肝癌患者接受介入治疗后肝功能损伤程度的差异。方法对2008年10月至2011年10月收治的80例高HBVDNA滴度的原发性肝癌患者,Child A级50例,Child B级30例,均给予介入治疗,比较两组在介入治疗后6个月内肝功能损伤的差异。结果两组出现肝功能损害的时间均在介入治疗后2周～1个月内,差异无统计学意义(P>0.05);但两组肝功能恢复时间差异有统计学意义(P<0.05)。Child B级组患者肝功能指标在介入治疗后明显升高,损害程度主要为Ⅱ、Ⅲ度,差异与Child A级组比有统计学意义(P<0.05)。在介入治疗后2个月Child A级和B级患者肝功能正常率分别为83%和50%(P<0.01);4个月肝功能正常率分别为88%和67%(P>0.05);6个月肝功能正常率分别为92%和80%(P>0.05)。结论高HBVDNA滴度Child B级肝癌患者在接受介入治疗后,肝功能损害程度明显,损伤比例较高,提示介入治疗前联合HBVDNA滴度和Child分级评价介入治疗指征的重要性。
Objective To study the liver function damage in patients of hepatocellular carcinoma with high lever of HBVDNA between Child A and B after trans-catheter arterial 80 primary hepatocellular carcinoma patients with high lever HBVDNA. The subjects were divided into two groups： Child A group （50 cases） and Child B group（30 cases）. We compared the differences of the two groups in hepatic function damage in 6 months after TACE. Results The hepatic function damage happened from 2 weeks to 1 month in both Child A and Child B groups, and had no statistical significance, but the recovery time of liver function had statistical significance with Child B. The parameters of liver function were significantly higher in Child B after TACE. The normal liver function rate were 83% and 50% respectively in 2-month after TACE, and had significant difference（ P 〈 0.01 ）, 88% and 67% respectively in 4-month（P 〉 0.05 ）, 92% and 80% in 6-month（P 〉 0.05 ）. Conclusions The degree of liver function damage and the rate of liver function are more obviously in Child B with high lever of HBVDNA received TACE. It was important to estimate the indication curative of TACE by the lever of HBVDNA and Child-paugh score.
出处
《中国肿瘤外科杂志》
CAS
2013年第3期160-162,共3页
Chinese Journal of Surgical Oncology
